Engineered immune cells target brain tumors in new trial
NCT ID NCT03696030
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose and understand side effects. About 24 adults with recurrent brain or spinal lining metastases will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?